| answer text |
<p>The Multiple Sclerosis Risk-Sharing Scheme will remain in place until the publication
of the National Institute for Health and Care Excellence’s (NICE) final updated technology
appraisal guidance on disease modifying therapies for the treatment of multiple sclerosis.</p><p>As
long as they are clinically eligible, new and existing patients can continue to access
these therapies as part of the Scheme.</p><p>Once NICE’s appraisal has been completed,
the normal access arrangements will apply. National Health Service commissioners are
legally required to fund drugs and treatments recommended by NICE within three months
of NICE’s guidance being published. In the absence of a positive recommendation from
NICE, it is for commissioners to make decisions on whether to fund treatments based
on an assessment of the available evidence.</p>
|
 |
